This article is for informational and educational purposes only and does not constitute medical advice. Tirzepatide and retatrutide are supplied by Wholesale Peps as lyophilized research-grade material for in vitro laboratory use only and are not approved by the FDA for human or veterinary use. Retatrutide is an investigational compound that has not received regulatory approval for any indication.
Wholesale Peps is not affiliated with, endorsed by, or in any way connected to Eli Lilly and Company. This comparison is compiled from publicly available peer-reviewed literature for educational purposes only.
Tirzepatide is a dual GIP / GLP-1 receptor co-agonist. Retatrutide is a triple agonist that adds a third target — the glucagon receptor (GCGR) — to those same two incretin receptors. Both are 39-amino-acid, once-weekly peptides from Eli Lilly built on the same structural template; the added glucagon receptor is the central difference. In separate phase-3 trials retatrutide produced the larger mean weight reduction, but a key contrast remains maturity: tirzepatide is FDA-approved with a cardiovascular-outcomes trial, while retatrutide — despite positive pivotal phase-3 data (TRIUMPH-1) — is not yet approved and has no dedicated cardiovascular-outcomes result.
Tirzepatide
- Targets: GIPR + GLP-1R (dual)
- 39 amino acids · ~4,814 Da
- Half-life ~5 days (weekly)
- SURMOUNT-1 weight: ~−20.9% (Ph 3)
- FDA-approved; CV outcomes trial reported
- Brands: Mounjaro, Zepbound
Retatrutide
- Targets: GIPR + GLP-1R + GCGR (triple)
- 39 amino acids · ~4,731 Da
- Half-life ~6 days (weekly)
- TRIUMPH-1 weight: ~−25% (12 mg, 80 wk, Ph 3)
- Investigational; BLA planned Q1 2027
- No brand name (not yet approved)
Weight figures are from separate phase-3 trials (SURMOUNT-1, 72 wk; TRIUMPH-1, 80 wk) and are not a controlled head-to-head; retatrutide's phase-3 data are so far topline and congress reports with peer-reviewed publication pending. This summary describes published research and is not medical advice.
Researchers frequently compare tirzepatide vs retatrutide because both belong to the newest generation of incretin-based metabolic peptides, yet they differ in receptor targets, clinical maturity, and reported weight-loss outcomes. Tirzepatide and retatrutide are the dual- and triple-agonist members of Eli Lilly's incretin engineering lineage, and they are the most direct illustration of the "add another receptor" strategy that has driven metabolic peptide research. Both are once-weekly, albumin-bound, C20-acylated 39-amino-acid peptides that resist DPP-4 cleavage. Tirzepatide co-activates the GLP-1 receptor (GLP-1R) and the GIP receptor (GIPR); retatrutide activates those two plus the glucagon receptor (GCGR). Across their trial programs — the SURMOUNT and SURPASS trials for tirzepatide, and the phase-2 studies plus the pivotal phase-3 TRIUMPH program for retatrutide — the triple agonist has reported the larger weight reductions, plausibly driven by glucagon-mediated energy expenditure and hepatic fat mobilization; retatrutide's pivotal phase-3 obesity trial, TRIUMPH-1, reported positive topline results in 2026. The remaining distinction is evidence maturity and regulatory standing: tirzepatide is FDA-approved with a dedicated cardiovascular-outcomes trial, whereas retatrutide — though it now has pivotal phase-3 efficacy data — is not yet approved (a regulatory filing is planned for 2027), has no dedicated cardiovascular-outcomes result, and its phase-3 data are so far reported as topline and congress presentations with peer-reviewed publication pending. This page compares the two on mechanism, structure, pharmacokinetics, efficacy data, safety, and approval status. All referenced data derive from human clinical trials; in vitro applications of either compound are for receptor pharmacology and mechanistic research only.
1. Tirzepatide vs Retatrutide — Master Comparison Table
The table below summarizes the two compounds across the attributes most often searched. Figures are drawn from the peer-reviewed clinical literature and the compound profiles reviewed in depth on each individual research page. Efficacy values from separate trials are not directly interchangeable, and depend on the estimand and time point quoted; see the section on cross-trial limitations.
| Attribute | Tirzepatide | Retatrutide |
|---|---|---|
| Drug class | Dual GIP / GLP-1 receptor co-agonist | Triple GIP / GLP-1 / glucagon receptor agonist |
| Receptor targets | GLP-1R + GIPR | GLP-1R + GIPR + GCGR |
| Developer | Eli Lilly | Eli Lilly |
| Development code | LY3298176 | LY3437943 |
| Peptide length | 39 amino acids | 39 amino acids |
| Molecular weight | ~4,814 Da | ~4,731 Da |
| Fatty-acid acylation | C20 diacid | C20 diacid |
| Elimination half-life | ~5 days | ~6 days |
| Dosing interval | Once weekly (SC) | Once weekly (SC) |
| Peak trial weight change | SURMOUNT-1: ~−20.9% (15 mg, 72 wk, Ph 3) | TRIUMPH-1: ~−25% (12 mg, 80 wk, Ph 3) |
| Development stage | Approved; marketed | Investigational; pivotal Ph 3 reported, BLA planned 2027 |
| Cardiovascular outcomes | SURPASS-CVOT: demonstrated noninferiority to dulaglutide for major adverse cardiovascular events (MACE) | No dedicated MACE outcomes trial reported |
| Predominant adverse events | GI: nausea, diarrhea, vomiting, constipation | GI effects; plus dose-related heart-rate increase |
| Brand equivalents | Mounjaro, Zepbound | None (not approved) |
| First FDA approval | 2022 (Mounjaro, T2D) | Not approved |
2. The Core Difference: Two Receptors vs Three
Every downstream contrast between these two compounds traces back to a single design decision. Both molecules are engineered incretin-mimetics from the same developer, built on a GIP-derived backbone, stabilized against enzymatic breakdown, and acylated with a C20 fatty diacid for albumin binding and a long half-life. The difference is how many hormone receptors each one engages.
Tirzepatide is a dual co-agonist at the GLP-1 receptor (GLP-1R) and the GIP receptor (GIPR). Its receptor pharmacology is described as imbalanced and biased in experimental systems — roughly 5-fold greater potency at GIPR than GLP-1R in cAMP assays, and biased signaling at GIPR relative to native GIP [6]. This dual-incretin approach was the first of its kind to reach approval and set the efficacy benchmark that later compounds are measured against.
Retatrutide keeps both incretin receptors and adds a third: the glucagon receptor (GCGR). It is therefore a triple agonist of GIP, GLP-1, and glucagon receptors [4]. Just as the step from semaglutide to tirzepatide added GIPR to a GLP-1 monoagonist, the step from tirzepatide to retatrutide adds GCGR to the dual agonist. The rationale is that glucagon-receptor signaling contributes an energy-expenditure and hepatic-lipid axis that the two incretin receptors do not directly engage — a mechanism explored in more detail in section 6.
3. Structure & Pharmacokinetics Compared
Because both compounds come from the same engineering program, they are structurally more alike than semaglutide and tirzepatide are. Both are 39-residue peptides built on a GIP-derived scaffold, both use alpha-aminoisobutyric acid (Aib) substitutions to block DPP-4 cleavage, and both carry a C20 fatty diacid that enables reversible albumin binding to slow renal clearance [4]. Retatrutide's sequence is further modified to open up glucagon-receptor activity while retaining the two incretin activities.
| Property | Tirzepatide | Retatrutide |
|---|---|---|
| Backbone | GIP-derived, optimized for dual activity | GIP-derived, optimized for triple activity |
| Length | 39 amino acids | 39 amino acids |
| Non-coded residues | Aib at position 2 | Aib at positions 2 and 20; α-methyl-Leu at 13 |
| Acylation | C20 fatty diacid | C20 fatty diacid |
| Molecular weight | ~4,814 Da | ~4,731 Da |
| Albumin binding | High-affinity, albumin-bound | High-affinity, albumin-bound |
| Half-life | ~120 h (~5 days) | ~144 h (~6 days) |
| Route | Subcutaneous weekly | Subcutaneous weekly |
| Escalation rationale | Gradual titration for GI tolerance | Gradual titration for GI tolerance and heart-rate |
The half-lives of both compounds support once-weekly subcutaneous administration, and both rely on gradual dose escalation to improve tolerability. In in vitro terms, both are supplied as lyophilized powder and studied under buffer and concentration conditions that do not reproduce the albumin-binding, distribution, and clearance environment of systemic administration — a point that applies equally to receptor-binding and cAMP assays for either compound, and with particular force to retatrutide, whose three-receptor pharmacology is still being characterized.
4. Weight-Loss Data: SURMOUNT-1 vs TRIUMPH-1 (Phase 3 vs Phase 3)
The most-searched question about these two compounds is which produces more weight reduction. Both now have pivotal phase-3 obesity data, so the comparison is fairer than it once was — though still not a controlled head-to-head. Tirzepatide's ~−20.9% comes from SURMOUNT-1, a phase-3 trial of 2,539 adults over 72 weeks [2]. Retatrutide's pivotal phase-3 trial, TRIUMPH-1 (n=2,339, 80 weeks), reported roughly ~−25% at the 12 mg dose on the more conservative treatment-regimen estimand, with higher figures on the on-treatment estimand and in longer extensions; topline results were announced in 2026 and presented at the ADA Scientific Sessions, with peer-reviewed publication pending [8]. Retatrutide's earlier phase-2 obesity trial (n=338, 48 weeks) had already reported ~−24.2% at 12 mg [1], and the phase-3 result is consistent with it.
Approximate mean percent body-weight change from baseline. Tirzepatide value from SURMOUNT-1 (phase 3, 72 weeks, 15 mg) [2]; retatrutide values from TRIUMPH-1 (phase 3, 80 weeks; treatment-regimen estimand) [8]. Bars come from separate trials and are shown for reference, not as a controlled head-to-head. Retatrutide figures are from topline and congress reports and use the more conservative estimand; on-treatment and longer-extension values are higher. Verify exact figures from source publications when available.
Two observations matter. First, retatrutide's mid dose (9 mg) already produced a mean reduction (~−23.7%) exceeding tirzepatide's top-dose SURMOUNT-1 figure, and the 12 mg dose reached ~−25% on the treatment-regimen estimand, with higher on-treatment and longer-extension values reported [8]. Second, the exact "headline" number is estimand- and duration-dependent: TRIUMPH-1 ran to 80 weeks, and its on-treatment estimand and a 104-week extension report higher figures than the more conservative treatment-regimen value shown above, so a single percentage can range materially. The honest reading is that retatrutide has now shown very large pivotal phase-3 weight reductions that meet or exceed tirzepatide's — while the two have never been compared head-to-head, and retatrutide's phase-3 data are so far topline and congress reports rather than full peer-reviewed publications.
| Metric | Tirzepatide 15 mg (SURMOUNT-1) | Retatrutide 12 mg (TRIUMPH-1) |
|---|---|---|
| Mean weight change (top dose) | −20.9% | ~−25% (treatment-regimen) |
| Trial phase | Phase 3 | Phase 3 |
| Trial duration | 72 weeks | 80 weeks |
| Participants (total) | n=2,539 | n=2,339 |
| Placebo comparator | −3.1% | −3.9% |
| Regulatory status | Approved | Investigational (filing planned 2027) |
5. Evidence Maturity: Approved Dual Agonist vs Not-Yet-Approved Triple Agonist
This remains the most important part of an honest tirzepatide-vs-retatrutide comparison. The gap between the two has narrowed sharply now that retatrutide has pivotal phase-3 efficacy data — but it has not closed, because regulatory approval, cardiovascular-outcomes evidence, and full peer-reviewed publication are distinct milestones from a single positive efficacy trial.
Tirzepatide has completed a full phase-3 program (the SURPASS diabetes trials and the SURMOUNT obesity trials), earned FDA approval as Mounjaro (2022, type 2 diabetes) and Zepbound (weight management), and has a dedicated cardiovascular-outcomes trial, SURPASS-CVOT, which reported tirzepatide noninferior to dulaglutide for major adverse cardiovascular events. Its efficacy and safety are characterized across tens of thousands of participants and years of post-approval use.
Retatrutide now has pivotal phase-3 efficacy data, but is still investigational. Its TRIUMPH phase-3 program has begun reporting: TRIUMPH-1 (obesity, n=2,339) met its endpoints with large weight reductions [8], and TRIUMPH-3 (severe obesity with established cardiovascular disease) reported positive topline weight results in 2026. Its earlier phase-2 trials in obesity [1], type 2 diabetes [3], and metabolic-dysfunction-associated steatotic liver disease (MASLD) [5] remain its peer-reviewed evidence base. What retatrutide still lacks: regulatory approval (Eli Lilly has said it plans to file for FDA approval in early 2027), a brand name, a dedicated cardiovascular-outcomes (MACE) trial, the TRIUMPH-2 diabetes readout, and full peer-reviewed publication of the phase-3 results, which are so far topline announcements and congress presentations.
There is also no head-to-head trial between the two. Unlike semaglutide and tirzepatide, which were compared directly in SURPASS-2 [7], tirzepatide and retatrutide have never been randomized within the same study. Every "retatrutide vs tirzepatide" comparison — including this one — therefore rests on cross-trial inference.
| Evidence dimension | Tirzepatide | Retatrutide |
|---|---|---|
| Highest phase reported | Phase 3 (completed) | Phase 3 (reporting) |
| Regulatory status | FDA-approved | Investigational (filing planned 2027) |
| Cardiovascular outcomes | SURPASS-CVOT reported | No dedicated MACE trial |
| Phase-3 program | SURPASS / SURMOUNT (done) | TRIUMPH (reporting; TRIUMPH-2 pending) |
| Peer-reviewed phase-3 publication | Published | Pending (topline / congress) |
| Direct head-to-head vs the other | None | None |
6. The Glucagon Receptor: What the Third Target Adds
The whole rationale for a triple agonist rests on what glucagon-receptor (GCGR) agonism contributes beyond the two incretin receptors. This is also where the mechanistic story becomes a double-edged one.
On the benefit side, glucagon is not only a glucose-raising hormone. Glucagon-receptor signaling is associated with increased energy expenditure (thermogenesis) and with hepatic lipid mobilization and oxidation — the liver burning stored fat. In research models this axis is the proposed reason a triple agonist can drive greater weight reduction than incretin agonism alone, and it aligns with the pronounced liver-fat reductions retatrutide produced in its phase-2a MASLD study [5]. Neither semaglutide nor tirzepatide engages this pathway directly.
On the caution side, glucagon raises hepatic glucose output, which on its own would oppose the glucose-lowering goal of a metabolic compound. The design bet of a triple agonist is that the GLP-1 and GIP components — which drive glucose-dependent insulin secretion — offset the glucagon-mediated glucose rise, so net glycemic control is maintained. Retatrutide's phase-2 trials also reported dose-related increases in heart rate and, in some analyses, transient changes in glucose and other laboratory measures. These glucagon-linked considerations are part of why phase-3 confirmation of the compound's benefit-risk balance matters, and part of why its dose escalation is managed carefully.
7. Side Effects & Tolerability Compared
Because both compounds fully activate GLP-1R and GIPR, they share the incretin-class adverse-event profile. In both programs the most frequent adverse events were gastrointestinal — nausea, diarrhea, vomiting, and constipation — concentrated during dose escalation and predominantly mild to moderate. Both use gradual titration to improve tolerability, and in the retatrutide trial a lower 2 mg starting dose (versus 4 mg) reduced early GI events.
The differences stem from retatrutide's glucagon-receptor activity and its earlier stage of study. Retatrutide's trials reported dose-related increases in heart rate that are attributed in part to glucagon-receptor engagement, along with the transient metabolic changes noted above. Equally important, tirzepatide's safety profile is characterized across a completed phase-3 program and years of post-approval surveillance. Retatrutide now has phase-3 safety data from TRIUMPH-1 (n=2,339, 80 weeks) alongside its phase-2 trials, but it has no post-approval real-world record, its phase-3 adverse-event tables are not yet fully published, and rare or long-latency effects that only emerge over many years are, by definition, not yet fully characterized.
As GLP-1-receptor-active compounds, both also fall under the class-level contraindication derived from rodent carcinogenicity findings in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2). Individual tolerability varies, and this summary is not a substitute for professional medical assessment.
8. Approval & Availability Status
Much of the public search interest in these compounds uses brand names, but here the two are at very different regulatory stages — a difference worth stating plainly. Note that the research-grade material supplied by Wholesale Peps is unformulated compound for in vitro laboratory use only for both compounds; it is not any finished medicine.
| Peptide | Brand(s) | Status | Maker |
|---|---|---|---|
| Tirzepatide | Mounjaro | Approved — type 2 diabetes | Eli Lilly |
| Tirzepatide | Zepbound | Approved — weight management | Eli Lilly |
| Retatrutide | None | Investigational — phase-3 reported; BLA planned Q1 2027 | Eli Lilly |
In other words, "Mounjaro vs retatrutide" or "Zepbound vs retatrutide" is a comparison between an approved, marketed medicine and an investigational compound that — despite positive pivotal phase-3 data — has no approved product behind it yet. Both are Eli Lilly molecules from the same design lineage, but only tirzepatide has cleared the regulatory bar; retatrutide's filing is planned for early 2027. A product sold under a brand name is a finished, regulated medicine; the peptides discussed here are supplied only as lyophilized research material.
9. Limitations of This Comparison
Comparing an approved dual agonist against a not-yet-approved triple agonist studied in separate trials requires particular caution. The following limitations apply to essentially every "tirzepatide vs retatrutide" comparison, including this one.
Frequently Asked Questions
Common tirzepatide vs retatrutide questions, answered from the published research literature.
What is the difference between tirzepatide and retatrutide?+
Is retatrutide stronger than tirzepatide for weight loss?+
Is retatrutide FDA approved?+
What does the glucagon receptor add to retatrutide?+
Are tirzepatide and retatrutide made by the same company?+
Do tirzepatide and retatrutide have the same side effects?+
Does retatrutide have a brand name like Mounjaro or Zepbound?+
References
- Jastreboff AM, Kaplan LM, Friás JP, et al. "Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." New England Journal of Medicine. 2023;389(6):514–526. doi:10.1056/NEJMoa2301972
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)." New England Journal of Medicine. 2022;387(3):205–216. doi:10.1056/NEJMoa2206038
- Rosenstock J, Frias J, Jastreboff AM, et al. "Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial." The Lancet. 2023;402(10401):529–544. doi:10.1016/S0140-6736(23)01053-X
- Coskun T, Urva S, Roell WC, et al. "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss." Cell Metabolism. 2022;34(9):1234–1247. doi:10.1016/j.cmet.2022.07.013
- Sanyal AJ, Kaplan LM, Friás JP, et al. "Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial." Nature Medicine. 2024;30:2037–2048. doi:10.1038/s41591-024-03018-2
- Willard FS, Douros JD, Gabe MBN, et al. "Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist." JCI Insight. 2020;5(17):e140532. doi:10.1172/jci.insight.140532
- Friás JP, Davies MJ, Rosenstock J, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)." New England Journal of Medicine. 2021;385(6):503–515. doi:10.1056/NEJMoa2107519
- Eli Lilly and Company. "Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1)." Press release, 2026; topline results presented at the American Diabetes Association 86th Scientific Sessions, 2026. Full peer-reviewed publication pending; figures cited are from company and congress reports and should be verified against the final publication when available.